Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06GDH
|
||||
| Former ID |
DCL000763
|
||||
| Drug Name |
DA-5018
|
||||
| Synonyms |
Capsavanil; Davasaicin; Da 5018; KR-25018; Benzeneacetamide, 4-(2-aminoethoxy)-N-(3-(3,4-dimethylphenyl)propyl)-3-methoxy-, monohydrochloride; 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)propyl]acetamide; 2-[4-(2-aminoethoxy)-3-methoxyphenyl]-N-[3-(3,4-dimethylphenyl)propyl]acetamide hydrochloride
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Diabetic neuropathy; Postherpetic neuralgia [ICD9: 053.19, 250, 250.6, 356.0, 356.8; ICD10:E11.21, G44.847, G53.0, G64, G90.0] | Discontinued in Phase 2 | [1] | ||
| Company |
Dong-A
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H30N2O3
|
||||
| Canonical SMILES |
CC1=C(C=C(C=C1)CCCNC(=O)CC2=CC(=C(C=C2)OCCN)OC)C
|
||||
| InChI |
1S/C22H30N2O3/c1-16-6-7-18(13-17(16)2)5-4-11-24-22(25)15-19-8-9-20(27-12-10-23)21(14-19)26-3/h6-9,13-14H,4-5,10-12,15,23H2,1-3H3,(H,24,25)
|
||||
| InChIKey |
VVMIHZHLNJMAQP-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 147497-64-1
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Vanilloid receptor 1 | Target Info | Modulator | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Trk receptor signaling mediated by the MAPK pathway | ||||
| Trk receptor signaling mediated by PI3K and PLC-gamma | |||||
| Reactome | TRP channels | ||||
| References | |||||
| REF 1 | Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.